

CELGENE CORP /DE/  
Form S-8  
July 28, 2016

As filed with the Securities and Exchange Commission on July 28, 2016

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

*UNDER*

*THE SECURITIES ACT OF 1933*

CELGENE CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction of  
Incorporation or Organization)

22-2711928  
(I.R.S. Employer  
Identification No.)

**86 Morris Avenue, Summit, New Jersey 07901**  
**(Address of Principal Executive Offices) (Zip Code)**

**Celgene Corporation 2008 Stock Incentive Plan**

**(Amended and Restated as of April 15, 2015)**

**(Full Title of the Plan)**

*Copy to:*

**Mark J. Alles**

**Chief Executive Officer**

**Celgene Corporation**

**86 Morris Avenue**

**Summit, New Jersey 07901**

**(Name and Address of Agent for Service)**

**(908) 673-9000**

**(Telephone Number, Including Area Code, of Agent For Service)**

**Robert A. Cantone, Esq.**

**Proskauer Rose LLP**

**Eleven Times Square**

**New York, New York 10036**

**(212) 969-3000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Smaller reporting company

**CALCULATION OF REGISTRATION FEE**

| Title Of Securities To Be Registered     | <b>Amount To Be Registered<sup>(1)</sup></b> | Proposed Maximum Offering Price Per Share | Proposed Maximum Aggregate Offering Price | <b>Amount of Registration Fee<sup>(3)</sup></b> |
|--|--|---|---|---|
| Common Stock, par value \$0.01 per share | 17,500,000                                   | \$ 106.47                                 | (2) \$1,863,181,250.00(2)                 | \$ 187,622.35                                   |

This Registration Statement covers 17,500,000 additional shares of common stock, par value \$0.01 per share, of Celgene Corporation (the “Registrant” or the “Corporation”) available for issuance pursuant to awards under the Corporation’s 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) (the “Plan”). In accordance (1) with Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement also covers any additional shares of common stock of the Registrant that become issuable pursuant to awards by reason of any stock dividend, stock split, recapitalization or other similar transaction that results in an increase in the number of the outstanding shares of common stock of the Registrant.

Calculated solely for purposes of this offering under Rules 457(c) and 457(h) under the Securities Act of 1933, as (2) amended, on the basis of the average of the high (\$107.48) and low (\$105.46) selling prices per share of common stock of the Registrant on July 21, 2016, as reported on the Nasdaq Global Select Market.

Pursuant to General Instruction E to Form S-8, a filing fee is only being paid with respect to the registration of 17,500,000 additional securities for the Plan. A Registration Statement on Form S-8 has been filed previously on each of January 4, 1999 (Registration No. 333-70083), June 20, 2000, March 21, 2001 (Registration No. 333-39716), July 26, 2001 (Registration No. 333-65908), August 14, 2003 (Registration No. 333-107980), June 30, 2005 (Registration No. 333-126296), November 8, 2006 (Registration No. 333-138497), July 31, 2008 (Registration No. 333-152655), July 31, 2009 (Registration No. 333-160955), November 2, 2011 (Registration No. 333-177669), October 29, 2012 (Registration No. 333-184634), October 30, 2013 (Registration No. 333-191996), October 28, 2014 (Registration No. 333-199638) and November 5, 2015 (Registration No. 333-207840) for the existing securities under the Plan.

**EXPLANATORY NOTE**

Incorporation by Reference. This Registration Statement is filed pursuant to General Instruction E to Form S-8. The contents of the Registration Statement on Form S-8 (Registration No. 333-207840) are incorporated herein by reference and made a part hereof.

Registration of Additional Shares of Common Stock Under the Plan. This Registration Statement on Form S-8 is filed by the Registrant to register an additional 17,500,000 shares of common stock, par value \$0.01 per share (the “Common Stock”), of Celgene Corporation (the “Registrant” or the “Corporation”), which may be awarded under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) (the “Plan”) pursuant to an amendment of the Plan approved by the Corporation’s Board of Directors on April 13, 2016, effective and approved by the stockholders of the Registrant on June 15, 2016.

## PART II

### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### Item 3. Incorporation of Documents by Reference.

The contents of the Registration Statement on Form S-8 previously filed with the Securities and Exchange Commission (the "Commission") on November 5, 2015 (Registration No. 333-207840) by the Corporation are incorporated herein by reference. In addition, the following new documents filed with the Commission by the Corporation are incorporated herein by reference:

- (a) the Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Commission on February 11, 2016;
- (b) the Corporation's Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2016 and June 30, 2016, filed with the Commission on May 3, 2016 and July 28, 2016, respectively;
- (c) the Corporation's Current Reports on Form 8-K, filed with the Commission on January 7, 2016, January 11, 2016 (other than with respect to Item 2.02 and Exhibit 99.1 in one of two Form 8-K filings on that date), February 12, 2016, March 4, 2016, March 7, 2016, April 18, 2016, June 15, 2016, and July 26, 2016.
- (d) the portions of the Definitive Proxy Statement on Schedule 14A for the 2016 annual meeting of stockholders held on June 15, 2016 to the extent incorporated by reference in the Annual Report on Form 10-K for the year ended December 31, 2015; and
- (e) the description of the Company's Common Stock contained in the Corporation's Registration Statement on Form 8-A, File No. 0-16132, including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, subsequent to the effective date of this Registration Statement, prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents. In no event, however, will any information that the Registrant

discloses under Item 2.02 or Item 7.01 of any Current Report on Form 8-K that the Registrant may from time to time furnish to the Commission be incorporated by reference into, or otherwise become a part of, this Registration Statement. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of this Registration Statement, except as so modified or superseded.

**Item 8. Exhibits.**

**Exhibit  
No. Description**

|      |  |
|------|--|
| 5    | Opinion of Proskauer Rose LLP*   |
| 23.1 | Consent of KPMG LLP*   |
| 23.2 | Consent of Proskauer Rose LLP (included in Exhibit 5)*   |
| 24   | Power of Attorney*   |
| 99.1 | Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) (incorporated by reference to Exhibit 10.1 to the Corporation's Current Report on Form 8-K filed with the Commission on June 18, 2015), as amended effective June 15, 2016 (such amendment incorporated by reference to Exhibit 10.1 to the Corporation's Current Report on Form 8-K filed with the Commission on June 15, 2016) |

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Summit, State of New Jersey on July 28, 2016.

**CELGENE  
CORPORATION**

By: /s/ Mark J. Alles  
 Mark J. Alles  
 Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

| <b>Signature</b>                         | <b>Title</b>  | <b>Date</b>   |
|--|---|---------------|
| /s/ Mark J. Alles<br>Mark J. Alles       | Chief Executive Officer (Principal Executive Officer)   | July 28, 2016 |
| /s/ Peter N. Kellogg<br>Peter N. Kellogg | Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | July 28, 2016 |
| /s/ Robert J. Hugin<br>Robert J. Hugin   | Executive Chairman and Director   | July 28, 2016 |
| *<br>Richard W. Barker,<br>D.Phil.       | Director  | July 28, 2016 |
| *<br>Michael W. Bonney                   | Director  | July 28, 2016 |
| *<br>Michael D. Casey                    | Director  | July 28, 2016 |

|                              |          |               |
|------------------------------|----------|---------------|
| *                            | Director | July 28, 2016 |
| Carrie S. Cox                |          |               |
| *                            | Director | July 28, 2016 |
| Jacquelyn A. Fouse,<br>Ph.D. |          |               |
| *                            | Director | July 28, 2016 |
| Michael A. Friedman,<br>M.D. |          |               |
| *                            | Director | July 28, 2016 |
| Julia A. Haller, M.D.        |          |               |
| *                            | Director | July 28, 2016 |
| Gilla Kaplan, Ph.D.          |          |               |
| *                            | Director | July 28, 2016 |
| James J. Loughlin            |          |               |
| *                            | Director | July 28, 2016 |
| Ernest Mario                 |          |               |

\*By: /s/ Robert J. Hugin  
Robert J. Hugin  
*Attorney-in-Fact*



**EXHIBIT INDEX**

| <b>Exhibit No.</b> | <b>Description</b>   |
|--------------------|--|
| 5                  | Opinion of Proskauer Rose LLP*   |
| 23.1               | Consent of KPMG LLP*   |
| 23.2               | Consent of Proskauer Rose LLP (included in Exhibit 5)*   |
| 24                 | Power of Attorney*   |
| 99.1               | Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015) (incorporated by reference to Exhibit 10.1 to the Corporation's Current Report on Form 8-K filed with the Commission on June 18, 2015), as amended effective June 15, 2016 (such amendment incorporated by reference to Exhibit 10.1 to the Corporation's Current Report on Form 8-K filed with the Commission on June 15, 2016) |

\* Filed herewith